ArticleParticle and fibre toxicology2025
Comparative toxicity study of three surface-modified titanium dioxide nanoparticles following subacute inhalation.
Article in Particle and fibre toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Pneumoconiosis Renaissance: Revisiting the Pulmonary Pathology of Poorly Soluble Low Toxicity Particles: Insights from Rodent Inhalation Studies on Titanium Dioxide Nanoparticles.Nanomaterials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to compare the toxic effects of three different titanium dioxide nanoparticles encoded in the European nanomaterial repository as NM-103 (rutile, hydrophobic), NM-104 (rutile, hydrophilic), and NM-105 (anatase/rutile, hydrophilic), suggesting different toxic potentials after uptake in the lungs. Wistar rats were exposed by nose-only inhalation to aerosol concentrations of 3, 12 and 48 mg/m
resultsBronchoalveolar lavage fluid from the groups exposed to low concentrations of NM-103 or NM-104 presented slight inflammation. In the mid- and high-exposure groups, this was also present for the NM-105 group, however, weaker than those of NM-103 and NM-104. Histologically, all three groups presented similar distributions of particles in the respiratory tract. Although marginal differences in the degree of some changes exist, no obvious differences in the degree or characteristics of the induced lesions were observable. In general, compared with the higher exposure groups, all the middle exposure groups presented a greater accumulation and aggregation of macrophages at the terminal bronchi. Using transmission electron microscopy, particles were detected mainly in intraalveolar macrophages, followed by type 1 pneumocytes in the low- and mid-concentration groups and intraalveolar free particles in the high-concentration groups. Compared with the other groups, the NM-103 group presented greater numbers of free particles in the alveoli and fewer in the macrophages. With image analysis, the movement of particles to the bronchus-associated lymphoid tissue and lymph nodes could be detected comparably for the three different particle types.
conclusionsThe no observed adverse effect concentration was 3 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.